650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Regular and Young Investigator Award Abstracts

Clinical Trial In Progress

650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

	Abstract	Full	Pdf
Nov 2023	258	0	23
Dec 2023	48	0	8
Jan 2024	65	0	5
Feb 2024	42	0	2
Mar 2024	22	0	3
Apr 2024	46	0	8
May 2024	28	0	0
Jun 2024	35	0	4
Jul 2024	18	0	2
Aug 2024	36	0	5
Sep 2024	36	0	5
Oct 2024	44	0	3
Nov 2024	40	0	3
Dec 2024	44	0	3
Jan 2025	47	0	10
Feb 2025	2	0	4
Mar 2025	0	0	5
Apr 2025	0	0	5
May 2025	0	0	5
Jun 2025	3	0	3
Total	814	0	106